Jacobi Capital Management LLC Has $5.08 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Jacobi Capital Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 35,157 shares of the company’s stock after selling 1,619 shares during the quarter. Jacobi Capital Management LLC’s holdings in Johnson & Johnson were worth $5,084,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Richard W. Paul & Associates LLC grew its holdings in shares of Johnson & Johnson by 1.5% during the 4th quarter. Richard W. Paul & Associates LLC now owns 6,567 shares of the company’s stock worth $950,000 after purchasing an additional 100 shares in the last quarter. Metis Global Partners LLC grew its holdings in shares of Johnson & Johnson by 1.4% during the 4th quarter. Metis Global Partners LLC now owns 140,714 shares of the company’s stock worth $20,350,000 after purchasing an additional 1,956 shares in the last quarter. West Michigan Advisors LLC grew its holdings in shares of Johnson & Johnson by 12.9% during the 4th quarter. West Michigan Advisors LLC now owns 4,458 shares of the company’s stock worth $645,000 after purchasing an additional 509 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of Johnson & Johnson by 8.4% during the 4th quarter. Fisher Asset Management LLC now owns 8,194,304 shares of the company’s stock worth $1,185,060,000 after purchasing an additional 634,105 shares in the last quarter. Finally, Maripau Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $267,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $167.08 on Tuesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market capitalization of $402.26 billion, a price-to-earnings ratio of 25.12, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The business has a 50-day moving average of $151.33 and a 200-day moving average of $156.08.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the firm posted $2.29 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Leerink Partners dropped their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Barclays upped their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Guggenheim increased their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.